Efficacy and safety of nanoparticles of glibenclamide and organomodified layered double hydroxides in diabetics rats.

Autor: Damasceno Leão A; Federal University of Pernambuco-UFPE, Department of Pharmaceutical Sciences, University, Recife, Brazil. Electronic address: amanda.damascenoleao@ufpe.br., Ribeiro da Silva J; Federal University of Pernambuco-UFPE, Department of Pharmaceutical Sciences, University, Recife, Brazil., Fontana Agostini J; Federal University of Pernambuco-UFPE, Department of Pharmaceutical Sciences, University, Recife, Brazil., Dal Santo G; Federal University of Pernambuco-UFPE, Department of Pharmaceutical Sciences, University, Recife, Brazil., Duarte Vieira L; Federal University of Pernambuco-UFPE, Department Physiology and Pharmacology, University, Recife, Brazil., da Costa Silva Neto J; Federal University of Pernambuco-UFPE, Department Physiology and Pharmacology, University, Recife, Brazil., Rodrigues de Lima Porto Ramos K; Federal University of Pernambuco-UFPE, Department of Pharmaceutical Sciences, University, Recife, Brazil., Gonçalves da Silva T; Federal University of Pernambuco-UFPE, Department of Pharmaceutical Sciences, University, Recife, Brazil., Alvarez-Lorenzo C; University of Santiago de Compostela-USC, Department of Pharmacology, Pharmacy and Pharmaceutical Technology, iMATUS and IDIS, 15782, Santiago de Compostela, Spain., Gonçalves Wanderley A; Federal University of São Paulo-UNIFESP, Department of Pharmaceutical Sciences, University, Diadema, Brazil., Lamartine Soares-Sobrinho J; Federal University of Pernambuco-UFPE, Department of Pharmaceutical Sciences, University, Recife, Brazil.
Jazyk: angličtina
Zdroj: International journal of pharmaceutics [Int J Pharm] 2023 Mar 05; Vol. 634, pp. 122678. Date of Electronic Publication: 2023 Feb 02.
DOI: 10.1016/j.ijpharm.2023.122678
Abstrakt: Glibenclamide (GB) is an important drug in the treatment of type II diabetes mellitus (DM II); however, its low solubility causes variability in its oral bioavailability, negatively affecting the pharmacological treatment. Nanoparticles (NP) of GB and organophilized Layered Double Hydroxide (LDH) were developed to improve oral bioavailability and tested in streptozotocin-induced diabetic rats to evaluate therapeutic efficacy and safety. Blood glucose was measured for 12 h or after 28 days of treatment. In addition, body weight, water and feed consumption, hematological, biochemistry and morphological parameters and markers of oxidative stress were determined. After the treatment, GB with LDH normalized the blood glucose level, indicating a better release profile. Water and feed intake and body weight of animals treated with GB and GB with LDH were closer to the normoglycemic group and did not indicate signs of toxicity of the nanoparticles. The biochemical, hematological and histological results also showed no significant changes related to nanotoxicity. The combination of GB with LDH proved to be critical in the oxidative balance, as it reduced the oxidative stress of vascular tissue. In conclusion, NPs are a potential controlled release system for the treatment of DM II.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2023 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: